Review

Mechanistic Aspects and Therapeutic Potential of Quercetin against COVID-19-Associated Acute Kidney Injury

Lúcio Ricardo Leite Diniz 1,*, Marilia Trindade de Santana Souza 2, Allana Bruna Sucupira Duarte 3 and Damião Pergentino de Sousa 3

1 Department of Nursing, College of Nordeste da Bahia, 48590-000 Coronel João Sá, Bahia, Brazil
2 Pharmacy Center, Uninassau University, 49075479 Aracaju, SE, Brazil; biomari@hotmail.com
3 Department of Pharmaceutical Sciences, Federal University of Paraíba, 58051-970 João Pessoa, PB, Brazil; allanabrunna@gmail.com (A.B.S.D.); damiao_desousa@yahoo.com.br (D.P.d.S.)

* Correspondence: luciodiniz@yahoo.com.br; Tel.: +55-75-3286-2268

Academic Editor: H.P. Vasantha Rupasinghe
Received: 10 November 2020; Accepted: 3 December 2020; Published: 7 December 2020

Abstract: The inflammatory mediator and oxidant agent storm caused by the SARS-CoV-2 infection has been strongly associated with the failure of vital organs observed in critically ill patients with coronavirus disease 2019 (COVID-19) and the death of thousands of infected people around the world. Acute kidney injury (AKI) is a common renal disorder characterized by a sudden and sustained decrease in renal function with a critical influence on poor prognosis and lethal clinical outcomes of various etiologies, including some viral infection diseases. It is known that oxidative stress and inflammation play key roles in the pathogenesis and development of AKI. Quercetin is a natural substance that has multiple pharmacological properties, such as anti-inflammatory action, and is used as a dietary supplement. There is evidence of the anti-coronavirus activities of this compound, including against the target SARS-CoV-2 3CLpro. The ability to inhibit coronavirus and its inflammatory processes is strongly desired in a new drug for the treatment of COVID-19. Therefore, in this review, the dual effect of quercetin is discussed from a mechanistic perspective in relation to AKI kidney injury and its nephroprotective potential to SARS-CoV-2 patients.

Keywords: natural products; medicinal plants; flavonoids; antioxidant; anti-inflammatory activity; nephroprotective activity; renoprotective activity; SARS-CoV; Middle East respiratory syndrome virus; coronavirus

1. Introduction

Coronavirus disease 2019 (COVID-19) has killed more than one million people with SARS-CoV-2 worldwide, and it continues creating great concern for the world medical community due to the continually elevated number of deaths caused by COVID-19 [1–3]. Recent clinical reports have indicated that COVID-19 may lead to severe and fatal respiratory complications and even to other organ failures, such as renal failure [4–6]. The increasing number of studies that relate a substantial number of patients with SARS-CoV-2 with acute kidney injury (AKI) have suggested that the impairment of renal functions, such as the retention of waste products of cellular metabolism and the lack of maintaining fluids, electrolytes, and acid–base homeostasis, contributes to the worsening of clinical outcomes and consequently to the lethality of COVID-19 [7–10]. AKI is a common renal disorder characterized by a sudden and sustained decrease in renal function with a critical influence on poor prognosis and lethal clinical outcomes of various etiologies, including cardiovascular diseases, diabetes, and sepsis [11,12].

The unavailability of specific treatment and the inability to accurately predict a timeline for an effective vaccine against COVID-19 [13–15] make it extremely necessary to test compounds with
therapeutic properties whose pharmacological safety and efficacy have been previously tested to inhibit, or at least attenuate, organ disorders strongly associated with the worsening of clinical symptoms and lethality of COVID-19, including kidney disorders \[8-10,16\]. In this context, quercetin may be a very helpful therapeutic tool for the treatment of AKI induced by COVID-19. Quercetin is a widespread flavonoid found in a large variety of medicinal plants and dietary supplements present in oriental and occidental diets, such as green teas, oranges, lettuces, potatoes, onions, and tomatoes \[17,18\]. Furthermore, it has inhibitory activity against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) \[19\]. Numerous studies have shown the nephroprotective effects of quercetin against obstructive, oxidative, and inflammatory renal damage in a large spectrum of experimental models of AKI \[20-24\]. The antioxidant and anti-inflammatory properties have been credited as the main mechanisms by which quercetin inhibits the renal damages \[19,22,25-29\].

The present study aims to give an overview of the safety and effectiveness of quercetin on AKI induced by very diverse nephrotoxic stimuli. Its therapeutic potential for COVID-19-related renal injury could be evaluated through an evaluation of the current literature pertaining to the various cellular and molecular targets of AKI.

2. Materials and Methods

The present article was prepared based on a survey of the literature pertaining to quercetin and AKI. The search, performed in the PubMed database, included studies published until August 2020 and used the following keywords: quercetin, coronavirus, COVID-19, SARS-COV-2, AKI, acute renal failure, virus-induced AKI, SARS-COV-2-induced AKI, and COVID-19-induced AKI. Only studies in which the renoprotective effects of quercetin were investigated under experimental or clinical AKI in accordance with Kidney Disease: Improving Global Outcomes (KDIGO) stages 1, 2, or 3 definitions were selected. Results obtained from quercetin-derived compounds or a combination of quercetin with other bioactive drugs on nephroprotective properties were not considered. The scientific publications were selected from studies published in the English language.

3. General Aspects of Acute Kidney Injury

AKI is a common renal disorder characterized by a sudden (1 to 7 days) and sustained (more than 24 h) decrease in renal function with a critical influence on poor prognosis and lethal clinical outcomes of various etiologies and that contributes to the risk of long-term morbidity and death \[30-33\]. AKI is directly associated with serious clinical complications, including the retention of waste products of cellular metabolism that leads to the rise in cytotoxic substance levels, the alteration of drugs’ concentrations that reduces their pharmacological safety, and the lack of maintaining fluids, electrolytes, and acid–base homeostasis, which in turn are closely linked to alterations in blood pressure control, neuromuscular excitability, and metabolic disturbance \[6,7,9\]. In addition, AKI produces diverse inflammatory mediators and vasoactive agents that act on the kidney as well as distant organs, playing an important pathological role in the genesis and development of several diseases \[34,35\]. The course of AKI can vary from single hit and complete recovery to multiple hits that might lead to renal failure requiring dialysis, the development and progression of chronic kidney disease (CKD), and death \[32,36\]. Around the world, the incidence of AKI is about 20% of hospitalized patients and can reach up to more than 50% of all critically ill patients in intensive care units (ICUs) \[33,37,38\]. The development of AKI is directly associated with the prevalence and clinical outcome of hypertension, diabetes, and sepsis in ICU settings \[32,39\]. In a study carried out by Dylewska et al. \[40\], it was observed that the prevalence of hypertension was 70%, with the highest rate in post-renal AKI (85%), followed by renal AKI (75%), and pre-renal AKI (30%). In recent years, the world incidence of diabetes-induced AKI of hospitalized patients has reached more than 30% in diabetic adults, accompanied by an overall increased morbidity \[35\]. Regarding sepsis, up to 57% of all critically ill patients suffer from AKI \[41,42\].
Moreover, sepsis appears to be the most frequent contributing factor for the development of AKI. Studies indicate that AKI is caused by about 50% of sepsis cases worldwide [33,39].

Preliminary findings have shown that the etiology and prevalence of AKI vary, mainly due to different aspects of the sample evaluated (i.e., animal species, sex, age, and comorbidity), differences in the income levels of countries (with low-to-middle income countries showing more severity and a higher incidence of AKI than high-income countries), and differences in AKI classification criteria [32,38,43,44]. Throughout the last two decades, the AKI definition has been mainly based on the RIFLE (Risk, Injury, Failure, Loss, End-Stage Kidney Disease), Acute Kidney Injury Network (AKIN), and Kidney Disease: Improving Global Outcomes (KDIGO) criteria and stages [43,44]. Until 2004, the diagnosis of AKI was based on urine output as well as blood urea nitrogen (BUN) and serum creatinine (SCr) levels. The lack of a precise biochemical definition for AKI led the Acute Dialysis Quality Initiative group to create the RIFLE criteria in 2004, establishing a multidimensional staged definition. RIFLE uses glomerular filtration rate (GFR) criteria in addition to SCr and urine output criteria. The Risk, Injury, and Failure stages were determined by increases in SCr ≥ 1.5-, 2-, and 3-fold from a known baseline, respectively [43–45]. In 2007, the Acute Kidney Injury Network (AKIN) definitions were created with criteria driven by observations of minor increases in SCr over a shorter time period (48 h). The Risk, Injury, and Failure categories of the RIFLE definition were replaced by stages 1, 2, and 3 and the GFR criteria were abandoned in the AKIN definitions. The diagnosis of AKI was assessed by a rise in SCr ≥ 0.3-mg/dl over 48h in AKIN stage 1 and an absolute rise in SCr > 26.4 µmol/l was added to the relative increase of 100% and 200% in SCr compared to baseline in AKIN stages 2 and 3, respectively. The current definition created by KDIGO is similar to the AKIN definition but the time frame is extended from 48 h to 7 days. The decrease in urinary output to less than 0.5 mL kg⁻¹ h⁻¹ for 6 h was also similar to the RIFLE and AKIN definitions [30,43–46]. The actual criteria used to define AKI and its stages are not entirely accepted by all researchers and clinicians, who consider SCr and urine output more accurate markers of kidney dysfunction than AKI; consequently, both parameters are not ideal markers of AKI [47]. Over the last few years, many urine or blood biomarkers of AKI have been proposed as adjunct diagnostics to SCr and urinary output to improve the early detection, differential diagnosis, and prognostic assessment of AKI [48,49]. The following are among the novel biomarkers of AKI:

- Neutrophil gelatinase-associated lipocalin (NGAL): lesions in the thick ascending loop of Henle and the intercalated cells of the collecting duct [49–51].
- Kidney injury molecule-1 (KIM-1): lesions in proximal tubule cells [44,49,52].
- Interleukin-18 (IL-18): lesions in collecting duct and tubular epithelial cells [48,49].
- Liver-type fatty acid-binding protein (L-FABP): lesions in proximal tubule cells [49].
- Calprotectin (S100A8/9): lesions in collecting ducts and infiltrating immune cells [48,50].

In general, the mechanisms involved in the pathophysiology of AKI are attributed to renal damage caused by ischemic process, oxidative stress, and inflammation [30,53]. Many pathophysiological mechanisms contribute to kidney tubular and endothelial cell injury and consecutive renal dysfunction observed in ischemic AKI, including reduced renal blood flow (RBF), renal tubular apoptosis, necrosis, and inflammation [54,55]. In RBF-independent microcirculatory dysfunction, inflammatory mediators, immune cell infiltration, and the deregulation of nitric oxide synthase lead to the redistribution of blood flow from renal medulla to the cortex, the deterioration of microcirculatory oxygenation, tubular cell damages, and the formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [35,41,54].

4. Viral Infections and Acute Kidney Injury

Kidneys are high-risk organs for viral invasion, and the presence of AKI represents poor prognosis and potentially fatal outcome in several virus diseases [56]. Therefore, avoiding or even controlling the progression of AKI during viral infection have become challenges for the medical community. Various kidney diseases are associated with viral infections, including infection caused by the HIV virus [57], Epstein–Barr virus [58], parvovirus B19 [59], hepatitis B virus (HBV) [60], hepatitis C virus...
(HCV) [61], Zika virus [62], dengue virus [63], and influenza A (H1N1) virus [64]. A large spectrum of prevalence and clinical manifestations are observed among viral diseases, ranging from mild and rare AKI caused by acute symptomatic Epstein–Barr virus infectious mononucleosis [58] to rapid deterioration of renal function, often resulting in the requirement of renal replacement therapy, as observed in hantavirus-type infection [51,58,65,66].

Virus-associated glomerular disease, such as membranous glomerulopathy, glomerulosclerosis, and membranoproliferative glomerulonephritis associated with HCV infection [67–69], as well as interstitial nephritis and necrotizing tubulointerstitial nephritis are common clinical manifestations caused by BK virus, cytomegalovirus, and adenovirus infections [56,59]. AKI-associated nephritis is also a common renal disorder observed in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) and adenovirus infections [60,70,71]. In the last decade, high incidences of AKI have been found in critically ill patients with severe acute respiratory syndrome (SARS) and influenza A (H1N1), while in turn a strong relation between AKI and mortality rate was also observed [72,73].

The pathological mechanisms behind virus-associated kidney injury manifestations are either immune complex deposition or immune reactions resulting in glomerular membrane proliferation, based on severe coagulopathy, endothelial damage, and increased vascular permeability [70,74,75]. Massive releases of myoglobin-, cytokine-, and humoral factor-mediated acute interstitial nephritis play an important role in many viral infections [67,76]. Histological investigation shows the presence of acute distal tubular necrosis and viral particles in epithelial cells as well as the Bowman’s capsule found in many viral diseases, which differ significantly from those reported in bacterial infection characterized by increased rates of apoptosis in renal tubular epithelia as well as leucocytic infiltration in glomeruli and capillaries [56,68,70].

One relevant aspect in the incidence and outcome of AKI in viral infection is the presence of comorbidities and coinfection, particularly in those patients with a longer ICU stay and/or immunodeficiency [77,78]. In this context, HIV-infected patients may be predisposed to acquiring new viral coinfections added to HIV-associated nephropathy (HIVAN), immune complex kidney disease, thrombotic microangiopathy, and drug-related injury [75]. Thus, the kidney diseases found in HIV patients, such as immunotactoid glomerulopathy and fibrillary glomerulonephritis, are usually more severe and complex than other virus-associated kidney injuries [79].

An important feature of virus-associated kidney injury is the presence of virus in the urine for long periods after initial infection [80]. Considering that neither CD4+ nor CD8+ T cells are detected in the kidney, even after a long period of viral infection, increasing evidence that virus can infect renal tubules without the recruitment of immune cells as a viral strategy for persistent survival has been reported [54,75,79]. Ou et al. [80] investigated the replication strategies and immune responses of kidney caused by the duck hepatitis A virus (DHAV) up to 280 days after virus infection. In accordance with preliminary findings that cytokines, interferons, and interleukins are vital for both antiviral responses and the pathogenesis of viral infection, the results showed a strong cytokine storm, including type I (IFN-α/β) and type II (IFN-γ) IFNs, Th1-related ILs (IL-1β/2/6), and Th2-related ILs (IL-4), followed by a sudden decrease in virus loads in the mesangial cells and vascular endothelial cells for early infection [80]. The cytokine storm was consistent with both viral decrease and kidney injury, which combined with the histopathological changes indicated a double-edged sword for the host defense, since it not only enhanced viral clearance but also had a pathogenic effect [54,56].

5. Coronavirus and Acute Kidney Injury

Even though a better understanding of the pathophysiologic mechanisms of COVID-19-associated AKI is needed, there is increasing evidence that AKI is prevalent in critically ill patients with SARS-CoV-2 infection and it is closely associated with the severity of COVID-19 [11,12,81,82]. Moreover, clinical data have suggested that AKI represents poor prognosis and is associated with high mortality of patients with SARS-CoV-2 in ICU settings, especially in those with underlying comorbidities and requiring renal replacement therapy [3,9]. For example, a study that analyzed the clinical characteristics
and complications in fatal cases with coronavirus disease 2019 (COVID-19) in Renmin Hospital of Wuhan University in China reported that 14 patients suffered from renal injury after the infection of SARS-CoV-2 in 92 deceased patients with COVID-19. AKI was determined based on levels of SCr, BUN, and GFR found in these 14 patients and compared with the cases without renal injury. The median levels of SCr, BUN, and GFR in cases with renal insufficiency were 262 µmol/L, 30 mmol/L, and 18 mL/min, respectively [83]. In a study performed with 138 patients with SARS-CoV-2 hospitalized in the ICU of Mount Sinai Hospital (New York, NY, USA), 49 cases of AKI, characterized by an increase in the SCr level from approximately 1.0 to 8.0 mg/dL, a rise in the BUN level from about 20 to 100 mg/dL, and an increase in the serum phosphorus level > 8 mg/dL, over three days, were diagnosed among patients with COVID-19 by the Nephrology Department of the hospital. The magnitude of the variance of renal function parameters depends on certain factors, such as age and pre-existing comorbidities. Based on the serum phosphorus level > 10 mg/dL and a parameter arbitrarily chosen, 9 of 49 patients were found with AKI, with a mean AKI duration before phosphorus levels reaching 10 mg/dL after six days. Among the 9 patients, 6 died, 2 recovered, and 1 experienced no change [16].

In an attempt to obtain a definite conclusion on the association between AKI and the risk of mortality in patients with COVID-19, Yang et al. [83] performed a systematic review and meta-analysis study, in which a total of 24 studies published up to 26 April 2020 were evaluated, by searching the PubMed, Web of Science, and China National Knowledge Infrastructure databases, involving 4963 confirmed COVID-19 patients. The results showed that the incidence of AKI was 1.3%, 2.8%, and 36.4% in mild or moderate cases, severe cases, and critical cases, respectively. Meanwhile, the incidence of AKI was 52.9% and 0.7% in non-survivors and survivors, respectively [84].

In a recent study based on the analysis of several clinical reports, Gagliardi et al. [85] related that up to 15% of the hospitalized COVID-19 patients had at least one kidney abnormality represented by increased BUN and reduced GFR, as well as 26–63% of patients presented proteinuria at admission or developed proteinuria during their stay in hospital. Moreover, the incidence of AKI in COVID-19 patients varied from 0.5% to 23%, with an interval from baseline visit to the onset of AKI of 7–15 days in median, and that mortality from the COVID-19 patients who developed AKI could be up to 13 times higher than those infected patients without clinical signs of AKI. In addition, the authors suggested that the high prevalence of kidney involvement at hospital admission of some COVID-19 patients may be associated with some factors, including report of previous renal impairments, patients’ age, severity of illness, and presence of diabetes and/or heart failure, which are all risk factors for AKI that contribute to a pro-inflammatory state with functional defects in their immune system, worsening the clinical conditions of COVID-19 patients [85].

It should be noted that, in spite of strong evidence of increasing kidney dysfunction caused by COVID-19 and of AKI being closely associated with the severity and prognosis of COVID-19 patients, the actual AKI incidence, in particular in ICUs, remains uncertain and may have been underestimated due to different causes, including the design of the studies, the lack of clear operational AKI definitions, the reported AKI stages, and the timeline of AKI onset incidences [4,5,8,81,82].

6. Quercetin: A Natural Polyphenol Compound with Pharmacological Properties for the Treatment of COVID-19-Induced Morbidities

Quercetin is a widespread flavonoid, more specifically a flavonol (3,5,7,3’4’-pentahydroxyflavone), with a broad range of pharmacological properties and is found in a large variety of medicinal plants and dietary supplements [17,18]. Very diverse foods containing quercetin are present in oriental and occidental diets. Among food-based sources of quercetin are black and green teas, nuts, apples, grapes, berries, oranges, lettuce, potatoes, onions, and tomatoes. Quercetin is also available at the market and can be used in the isolated form [17,18,86,87].

Preliminary investigations on the pharmacokinetic properties of oral and intravenous quercetin, at dose levels varying from 8 to 2000 mg/m², in humans have indicated that quercetin has a very poor oral bioavailability (~2%), with low oral absorption, ranging from 3% to 17%, distribution and
volume of distribution of 0.7–7.8 min and 3.7 L/m², respectively, and extensive metabolism and/or rapid elimination, as indicated by clearance of 0.23–0.84 L/min/m² and elimination half-life of 3.8–86 min [86–90]. In addition, the reported Cmax and Tmax of quercetin are 2.3 ± 1.5 µg/mL and 0.7 ± 0.3 h, respectively [89]. The low bioavailability of quercetin has limited its oral use in experimental and pharmaceutical studies. Consequently, parenteral routes of administration have been commonly used to investigate the biological properties of quercetin [86,87]. However, conjugated forms of quercetin’s glycosides (with different sugar types and sugar group conjugation sites or pharmaceutical formulations in which it is associated with materials that enhance the solubility and/or dissolution rate of lipophilic drugs in aqueous media such as cyclodextrin) have shown improved bioavailability and are frequently used to evaluate pharmacological activities of oral quercetin [88,89]. Previous studies have indicated that quercetin’s safety dose is about 1000 mg/m² and its main toxicological effects are emesis, hypertension, and hypokalemia [90].

In recent years, diverse pharmacological properties have been attributed to quercetin, such as cardioprotection in spontaneous and experimentally induced hypertension, inhibition of secondary biliary cirrhosis, prevention of platelet aggregation, as well as antiangiogenic, anticancer, antiallergic, antiulcer and anti-inflammatory properties [17,18,86,91–94]. In general, the majority of the beneficial effect of quercetin is associated with antioxidant effects mainly through free radical scavenging and metal chelation and anti-inflammatory properties through NF-κB inhibition [27,95–97].

In this context, quercetin has been extensively studied for essential pharmacological properties requested in the treatment of Covid-19 and coronavirus-induced organ injury, such as antiviral, anti-oxidative and anti-inflammatory activities [13,15,94]. Previous studies have reported that quercetin and quercetin-derived compounds, such as quercetin-3-β-galactoside, display potent inhibitory effect on 3C-like protease (3CL(pro)) of SARS-CoV and MERS-CoV, a vital enzyme for viral replication, leading to inhibition of both coronavirus replications [98,99].

Multiple studies in different cell types and in both animal and human models have supported the long-lasting anti-inflammatory properties of quercetin [17,18,94]. Briefly, in vitro studies have shown that quercetin inhibited both cyclooxygenase and lipoxygenase activities in guinea pig epithelial cells [100], reduced mRNA levels and TNFα, IL-1α, and apoptotic neuronal cell death induced by microglial activation [100] as well as inhibiting TNF-α and IL-8 production induced by lipopolysaccharide (LPS) in macrophages and lung A549 cells, respectively [101]. In rat liver epithelial cells, quercetin promoted the inhibition of arsenite-induced COX-2 expression mainly by blocking the activation of the PI3K signaling pathway [102]. It also inhibited Src- and Syk-mediated PI3K-(p85) tyrosine phosphorylation and subsequent TLR4/MyD88/PI3K complex formation that limits the activation of downstream signaling pathways in RAW 264.7 cells [103]. Quercetin inhibited the IL-1-induced IL-6 secretion in mast cells [104]. Other anti-inflammatory mechanisms, such as downregulation of MMP-1, VCAM-1, and CD80 expression produced by quercetin, were observed in human umbilical skin and vein endothelial cells [101]. Various animal experiments have supported the in vitro anti-inflammatory properties of quercetin. Studies using rodents showed a modulation of prostanoid synthesis and cytokine production promoted by quercetin. Stewart et al. [104] showed that quercetin caused a decrease in interferon-γ, interleukin-1x, and interleukin-4 from C57BL/6J mice, corroborating with the inhibition of macrophage-derived cytokines and nitric oxide produced by quercetin in Lewis rats previously reported [95]. In humans, the anti-inflammatory effect of quercetin remains not fully consistent with results from cell (in vitro) and animal (in vivo) studies [87]. According to data of studies with humans, the anti-inflammatory properties of quercetin appear to be dependent on the type of subject and their level of health. For example, it was observed that there was no significant anti-inflammatory effect promoted by quercetin in cyclists after intense exercise [105], whereas quercetin treatment promoted anti-inflammatory effects, evidenced by a decrease in nitric oxide, C-reactive protein, and γ-glutamyl transferase activity in elderly human subjects [106]. Thus, the outcomes in humans need to be carefully evaluated and further investigation must be done in order to support the results of tests in cells and animals aiming at a broad application in the future.
Polyphenolic compounds, such as the flavonoids, commonly show antioxidant properties due to the presence of phenolic rings that promote the electron donation and hydrogen atom transfer to free radicals, acting as free-radical scavengers, reducing agents, and quenchers of single oxygen formation [93,107]. The antioxidant properties of quercetin have been strongly evidenced in studies using cells and animals. Quercetin (10 µmol/L) inhibited oxidative stress promoted by H₂O₂ in HepG2 cells [108,109]. Chen et al. [109] reported that quercetin decreased apoptosis and ROS production and increased SOD levels in intestinal porcine enterocyte cells [109]. In addition, Meng et al. [110] showed that quercetin produced an increase in SOD, CAT, and glutathione peroxidase (GSH-Px) levels accompanied by a decrease in lipid peroxidation in rats subjected to experimental sepsis and chronic prostatitis/chronic pelvic pain syndrome [111].

In addition to the antiviral, anti-inflammatory and antioxidant actions of quercetin, some mechanisms of quercetin’s action on the regulation of ion transporters and channels are important for understanding vasodilation and the increase in blood flow involved in protective properties of quercetin against organ injury [112]. It has been demonstrated that quercetin activates Na⁺-K⁺-2Cl⁻ cotransporter 1 (NKCC1) that leads to elevation of the cytosolic Cl⁻ concentration ([Cl⁻]c), which in turn downregulates gene expression of ENaC and decreases Na⁺, K⁺-ATPase activity [113,114]. These actions contribute to the reduction in vascular contraction and the renal Na+ reabsorption that explain, at least in part, the effects of quercetin on the regulation of blood pressure and renal function [17,115].

7. Quercetin and Acute Kidney Injury

Over the last few years, the renoprotective effect of quercetin has been tested in a wide range of experimental models of AKI [20,46,53,116]. In general, the studies have shown that quercetin treatment, at doses varying from 1 to 100 mg/kg, promotes significant nephroprotective activity, evidenced by inhibition or attenuation of the increase in classical biomarkers of AKI in renal injuries of toxic, obstructive, and inflammatory origins [20,94,115,116]. As shown in Table 1, several studies using AKI models created for several nephrotoxic compounds, including cisplatin [24,117], methotrexate [118,119], contrast [120], NaF [121], HgCl₂ [122], manganese [123], cadmium [124], and ciprofloxacin [29], showed that pretreatment with quercetin orally avoided an increase in BUN and SCr and a lower decrease in the GFR of animals that received a high dose of a nephrotoxic agent. Similarly, quercetin treatment improved renal function, evidenced by lessened renal pathologies, and lowered BUN and SCr levels, and histological integrity has been reported in an experimental model of renal ischemia and reperfusion (I/R) injury and sepsis-induced AKI, the most common causes of AKI in ICUs worldwide [21,53,115]. Gholampour and Sadidi [125] related that oral treatment with quercetin inhibited kidney dysfunction, characterized by a significant decrease in creatinine clearance and histological damages in the I/R-induced AKI, by clamping renal arteries for 45 min followed by 24 h reperfusion [125]. Previously, Shoskes [21] had reported the renoprotective properties of quercetin on ischemia/reperfusion in rats who underwent 30 min of left renal pedicle occlusion with simultaneous right nephrectomy [21].

The nephroprotective effects of quercetin appear to be directly associated with the reduction of oxidative stress [53,94]. The improvement of renal function promoted by quercetin treatment is accompanied by control of the oxidant–antioxidant balance [26,94]. Data from various studies with different nephrotoxic origins have shown that quercetin inhibits a decrease in glutathione peroxidase, superoxide dismutase, and catalase activities and an increase in malondialdehyde levels (lipid peroxidation) in AKI caused by toxins or drugs, ischemia/reperfusion, and sepsis [25,26,125–127].

Another very important feature of the mechanism underlying the renoprotective property of quercetin has been attributed to its actions on different targets of inflammatory response involved in the genesis and progression of renal injuries [53,87,92]. Pretreatment with quercetin significantly inhibited TNF-α, IL-1β, and IL-6 production in mice with LPS-induced AKI [128,129]. In addition, quercetin also significantly inhibited TLR4, MyD88, and TRAF-6 expressions and NF-κBp65 activation in the kidneys of rats with LPS challenge [25,128]. Shu et al. [130] showed that quercetin blocked CD38, possessing ADP-ribosyl cyclase (ADPR-cyclase) and cyclic ADP-ribose hydrolase (cADPR-hydrolase), in a mouse.
model with LPS-induced AKI [130]. In addition, quercetin treatment promoted a decrease in the renal levels of iNOS and IL-12 and the excessive accumulation of extracellular matrix and interstitial fibrosis by antagonizing NF-κB signaling activation and TGF-β1/Smad2/3 signaling [29]. It was also observed that quercetin increased AMPK phosphorylation, inhibited mTOR phosphorylation, and activated autophagy observed in the kidneys of I/R mice, suggesting that quercetin might protect the kidney against the ischemic process by activating the AMPK-regulated autophagy signaling pathway [131].

Data from animal models of AKI and human biopsies have shown that macrophage is a major contributor to the inflammatory response to AKI. There are growing sources of evidence that quercetin ameliorates kidney injury via modulating macrophage polarization, which appears to be associated with downregulated activities of NF-κB p65 and IRF5, as well as by inhibiting ASK1/JNK3/caspase-3 by enhancing the Akt signaling pathway [28,132,133]. Quercetin also inhibited the infiltration of CD68+ macrophages, the proportion of F4/80+/CD11b+CD86+ macrophages, and the polarization of F4/80+/CD11b+CD206+ M2 macrophages in cultured macrophages from kidneys and spleens in mice after LPS injection, indicating a quercetin-induced inhibitory effect on inflammatory macrophage polarization [100,134,135]. Recently, Tan et al. [24] showed that quercetin reduced inflammatory mediators in LPS-induced bone marrow-derived macrophages (BMDMs) and in a cisplatin-induced AKI model, which were accompanied by downregulation of protein levels of Mincle, phosphorylation of Syk and NF-κB in kidney macrophage I, and upregulation of M2 macrophage activity [24,28].

Table 1. Pharmacological effect of quercetin in models of acute kidney injury (AKI).

| Models of Acute Kidney Injury (AKI) | Pharmacological Effect | Mechanism | Reference |
|------------------------------------|------------------------|-----------|-----------|
| Ischemia/reperfusion-induced AKI models | Renoprotective | Inhibited the decrease in creatinine clearance and tubular damage; | [21] |
| AKI induced by unilateral ischemia/reperfusion via left renal pedicle occlusion with simultaneous right nephrectomy | Anti-inflammatory | Attenuated expression of normal T-cell expressed and secretion of monocyte chemoattractant protein-1, and allograft inflammatory factor. | |
| AKI induced by right renal and the left femoral blood vessels ischemia for 30 min followed by reperfusion in rats | Antioxidant | Reduced the renal cortex xanthine oxidase levels; Increased the renal cortex of superoxide dismutase, glutathione peroxidase, and catalase activities. | [116] |
| AKI induced by left renal pedicle occlusion for 45 min followed by 60 min of reperfusion with contralateral nephrectomy in rats | Anti-inflammatory | Reduced the TBARS, TNF-α levels, MPO activity and protein carbonyl; | [115] |
| | Antioxidant | Increased the glutathione levels and the superoxide dismutase and catalase activities. | |
| Renal pedicles occluded after nephrectomy, ischemia was given for 45 min followed by reperfusion for 24 h | Renoprotective | Attenuated the renal dysfunction via reduction in the Scr and BUN levels; Increased the creatinine and urine clearance; Reduced the morphological damage; | [135] |
| | Antioxidant | Reduced the elevated lipid peroxidation; Restored the depleted renal antioxidant enzymes, such as glutathione reductase. | |
| AKI induced by non-traumatic vascular clamp applied to the left renal pedicle for 2 h and allowed to reperfusion for 6 h | Antioxidant | Decreased the MDA levels; Increased the GSH levels; | [128] |
| | Anti-inflammatory | Decreased the number of apoptotic, p53-positive cells as well as reduced the NF-κB and eNOS expressions. | |
| AKI induced by clamping renal arteries for 45 min followed by 24 h reperfusion | Renoprotective | Sustained creatinine clearance and fractional excretion of sodium; Reduced tubular damage; | [125] |
| | Antioxidant | Increased glutathione peroxidase and catalase activities; Inhibited the decrease in malondialdehyde levels. | |
Table 1. Cont.

| Models of Acute Kidney Injury (AKI) | Pharmacological Effect | Mechanism | Reference |
|------------------------------------|------------------------|-----------|-----------|
| Unilateral ureteral obstruction-induced renal fibrosis | Anti-inflammatory | Inhibited tubulointerstitial injury; Reduced the synthesis and release of inflammatory factors; Inhibited the infiltration of CD68+ macrophages in renal interstitium; Decreased levels of iNOS and IL-12, as well as the proportion of F4/80+/CD11b+/CD86+ macrophages; Inhibitory effects associated with downregulated activities of NF-κB p65 and IRF5, and thus led to the inactivation of upstream signaling TLR4/Myd88; Inhibited the polarization of F4/80+/CD11b+/CD206+ M2 macrophages; Reduced excessive accumulation of extracellular matrix and interstitial fibrosis by antagonizing the TGF-β1/Smad2/3 signaling. | [28] |

| Drug- or Toxin-induced AKI models | Renoprotective | Decreased the BUN and SCr; Preserved the normal renal morphology. | [126] |
|------------------------------------|---------------|-------------------------------------------------|-----------|
| Fe-NTA-Induced AKI | Antioxidant | Reduced the lipid peroxidation; Restored the depleted renal antioxidant enzymes, such as glutathione reductase, catalase, superoxide dismutase, and glutathione. | | |
| Cadmium-induced AKI | Renoprotective | Reduced of BUN, SCr and uric acid levels; Protected against the Cd-induced pathological condition, as tubular necrosis, degeneration, desquamation, thickening of basement membrane and luminal cast formation; Decreased the renal lipid peroxidation; Increased total sulfhydrol group, glutathione, vitamin C and vitamin E, and antioxidant enzymes, such as superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase, glutathione reductase, and glucose 6-phosphate dehydrogenase. | [124] |
| Ethambutol hydrochloride-induced AKI | Antioxidant | Reduced the elevated levels of serum uric acid, BUN, and SCr. | [20] |
| NaF-induced AKI | Antioxidant | Increased the superoxide dismutase activity. | | |
| Methotrexate-induced AKI | Renoprotective | Decreased the renal tubular degeneration and dilation, Decreased the number of apoptotic cells and caspase-3 expression, Decreased the malondialdehyde levels; Increased superoxide dismutase, glutathione peroxidase, and catalase levels; Lowered apoptotic index. | [118,119] |
| Mercury-induced AKI | Renoprotective | Decreased the renal accumulation of Hg in the kidney; Reduced urinary excretion of protein-based biomarkers, including clusterin, KIM-1, NGAL, MCP-1, TIMP-1, and VEGF; Protected against renal proximal tubular damage; Reduced apoptotic cell death in the kidney. | [122] |
| Valproic acid-induced AKI | Antioxidant | Decreased the lipid peroxidation and protein carbonyl; Reduced glutathione and nonprotein thiol levels. | [25] |
| Ciprofloxacin-induced AKI | Renoprotective | Decreased the malondialdehyde levels; Increased the superoxide dismutase and catalase activities. | [24] |
| Manganese-induced AKI | Renoprotective | Counteracted Mn-induced morphological glomerular damage; Decreased the expression of GRP78, CHOP, and caspase-3 proteins. | [123] |
Table 1. Cont.

| Models of Acute Kidney Injury (AKI) | Pharmacological Effect | Mechanism | Reference |
|-----------------------------------|------------------------|-----------|-----------|
| Cisplatin-induced AKI             | Renoprotective         | Maintenance of renal blood flow, BUN and SCr levels, and sodium fractional excretion; Decreased the NGAL and KIM-1 excretion; Reduced the rise in MDA and protein carbonyl; Increased the GSH, vitamin C, vitamin E, total antioxidant capacity, and total glutathione levels in the kidney tissue; Induced the gene expression and activities of catalase, superoxide dismutase, glutathione reductase, and glutathione peroxidase enzymes in the kidney tissue; Inhibited expression and secretion of IL-1β, IL-6, and TNF-α; Reduced the activity of Mincle/Syk/NF-κB signaling in vitro; Downregulated the protein levels of Mincle, phosphorylated Syk, and NF-κB in kidney macrophages; Inhibited M1, upregulated M2 macrophage activity; Reduced the early activation of stress kinases ERK, JNK and p38. Lowered NF-κB pathway and effector caspase activations. |
| Antioxidant                        |                        |           | [24,117,126] |
| Anti-inflammatory                  |                        |           |           |
| Contrast-induced AKI               | Renoprotective         | Inhibited the increase in SCr and albuminuria accompanied by a lower decrease in the GFR. |
| Lipopolysaccharide-induced AKI     | Renoprotective         | Relieved kidney dysfunction; Decreased the histopathological damage; Lowered the BUN and SCr levels. Reduced the inflammatory cell accumulation; Inhibited the Toll-like receptor-4, MyD88, and TRAF-6 expressions and NF-κBp65 activation in the kidneys; Inhibited the TNF-α, IL-1β, and IL-6 levels; Blockaded the CD38 expression of the macrophages possessing ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase; Inhibited the LPS-induced macrophage M1 polarization accompanied by diminished NF-κB signaling activation. |
| Sepsis-induced AKI models         |                        |           | [120]     |

8. **Quercetin: A Helpful Therapeutic Drug Against SARS-COV-2-Induced AKI?**

Quercetin is a safe widespread flavonoid, found in many medicinal plants and dietary supplements, that presents a broad range of biological effects in cells and animals [100]. Over the last few years, numerous studies have shown a significant renoprotective effect of quercetin against kidney injury induced by different nephrotoxic agents (see Table 1). As outlined above, quercetin showed nephroprotective effects against kidney injury directly associated with oxidative stress and inflammatory response, which lead, respectively, to the rise in renal levels of ROS/RNS and the massive release of inflammatory mediators, in very diverse animal models of AKI [17,56,87]. Quercetin was effective in blocking or attenuating kidney lesions and dysfunctions caused by sepsis, diabetic nephropathy, ischemia/reperfusion as well as renal damage induced by varied nephrotoxic substances [26,27,29,115]. In general, the renoprotective effect of quercetin is associated with antioxidant effects mainly through free radical scavenging and metal chelation [93], and anti-inflammatory properties by modulating macrophage polarization, via downregulated activities of NF-κB p65 and IRF5 [23,24].

We can take into account the following facts: the frequent onset of AKI in patients with SARS-CoV-2 represents a life-threatening complication and increased risk of death [4–9]; the unavailability of a specific treatment for COVID-19 and its clinical complications [1–3]; and experimental evidence of the renoprotective properties of quercetin [23–28]. The underlying mechanisms by which quercetin promotes renoprotection act directly on important mediators of the pathophysiology of coronavirus-induced AKI [117,118,126,128,129] (see Sections 4–7). Taken all together, it is plausible to consider quercetin as a promising drug to be tested against COVID-19-induced AKI in clinical trials.

Even though the results suggest that quercetin exhibited renoprotection, anti-inflammation, and antioxidant in vitro (cells) and in vivo (animals) activities, it often happens that studies in humans do not totally support the results from tests in cells and animals [100]. Thus, some relevant factors
related to both clinical trials and quercetin need to be further verified for a future broad application in humans. For example, the type of subject, their level of health, illness severity, and presence of comorbidities are some of factors that might affect the results and should be considered by physicians and researchers [85]. Moreover, route of administration, formulation, and toxicity are parameters linked to pharmacological properties of quercetin that must also be evaluated beforehand [86–89]. Many features of quercetin that may alter the extrapolation of experimental results to clinical trials have already been minimized, such as the association of quercetin with cyclodextrins to the formulation of the inclusion complexes that improve its aqueous solubility and dissolution rate, increasing the bioavailability and the oral use of quercetin [89]. The choice of therapeutic dose could be based on preliminary findings of quercetin’s safety dose of 945 mg/m² and the effective dose of quercetin used in previous studies in humans [87,88].

In conclusion, the present review provides scientific evidence that supports the use of quercetin as a useful tool for the treatment of renal function impairment, to avoid the worsening of the clinical condition and, consequently, the short- and long-term morbidity and deaths of patients infected with SARS-COV-2 (see Figure 1).

**Figure 1.** Quercetin as a helpful therapeutic drug against COVID-19-associated AKI.

**Funding:** This research was supported by the National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (CAPES).

**Conflicts of Interest:** The authors declare no conflict of interest.
## Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| 3CL(pro)     | 3c-Like Protease |
| ACLF         | Acute-On-Chronic Liver Failure |
| ADPR-cyclase | ADP-Ribosyl Cyclase |
| AKI          | Acute Kidney Injury |
| AKIN         | Acute Kidney Network |
| Akt          | Protein Kinase B |
| AMPK         | AMP-Activated Protein Kinase |
| ASK1         | Apoptosis Signal-Regulating Kinase 1 |
| BMDMs        | Bone Marrow-Derived Macrophages |
| BUN          | Blood Urea Nitrogen |
| cADPR-hydrolase | Cyclic ADP-Ribose Hydrolase |
| CoVs         | Coronaviruses |
| COVID-19     | Coronavirus disease 2019 |
| DHAV         | Duck Hepatitis A Virus |
| GFR          | Glomerular Filtration Rate |
| GSH-Px       | Glutathione Peroxidase |
| HBV          | Hepatitis B Virus |
| HCV          | Hepatitis C Virus |
| HIV          | Human Immunodeficiency Virus |
| HIVAN        | Human Immunodeficiency Virus-Associated Nephropathy |
| I/R          | Ischemia and reperfusion |
| ICU          | Intensive Care Unit |
| IL           | Interleukin |
| IL-18        | Interleukin-18 |
| iNOS         | Nitric Oxide Synthase |
| IRF5         | Interferon Regulatory Factor 5 |
| JNK3         | C-Jun N-Terminal Kinase 3 |
| KDIGO        | Kidney Disease: Improving Global Outcomes |
| KIM-1        | Kidney Injury Molecule-1 |
| L-FABP       | Liver-Type Fatty Acid-Binding Protein |
| LPS          | Lipopolysaccharide |
| MDA          | Malondialdehyde |
| MERS-CoV     | Middle East Respiratory Syndrome-Related Coronavirus |
| MMP-1        | Matrix Metalloproteinase-1 |
| MyD88        | Myeloid Differentiation Protein |
| NF-kB        | Nuclear Factor kB |
| NGAL         | Neutrophil Gelatinase-Associated Lipocalin |
| PI3K         | Phosphoinositide 3-Kinase |
| RBF          | Renal Blood Flow |
| RIFLE        | Risk, Injury, Failure, Loss, End-Stage Kidney Disease |
| RNS          | Reactive Nitrogen Species |
| ROS          | Reactive Oxygen Species |
| SARS         | Severe Acute Respiratory Syndrome |
| SARS-CoV     | Severe Acute Respiratory Syndrome Coronavirus |
| SCr          | Serum Creatinine |
| SOD          | Superoxide Dismutase |
| SYK          | Tyrosine-Protein Kinase |
| TGF-β1       | Transforming Growth Factor Beta |
| TNF-α        | Tumor Necrosis Factor Alpha |
| TRAF6        | Tumor Necrosis Factor Receptor-Associated Factor 6 |
References

1. Beaney, T.; Clarke, J.M.; Jain, V.; Golestaneh, A.K.; Lyons, G.; Salman, D.; Majeed, A. Excess mortality: The gold standard in measuring the impact of COVID-19 worldwide? J. R. Soc. Med. 2020, 113, 329–334. [CrossRef]

2. Becher, T.; Frerichs, I. Mortality in COVID-19 is not merely a question of resource availability. Lancet Respir. Med. 2020, 8, 832–833. [CrossRef]

3. Immovilli, P.; Morelli, N.; Rota, E.; Guidetti, D. COVID-19 mortality and health-care resources: Organization. Med. Intensiva. 2020, 1–2. [CrossRef]

4. Chen, L.; Liu, S.; Tian, J.; Pan, H.; Liu, Y.; Hu, J.; Wang, M.; Hou, X. Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China. Immun. Inflamm. Dis. 2020, 1–11. [CrossRef]

5. Grasselli, G.; Greco, M.; Zanella, A.; Albano, G.; Antonelli, M.; Bellani, G.; Bonanomi, E.; Cabrini, L.; Carlesso, E.; Castelli, G.; et al. Risk Factors Associated with Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 2020, 180, 1345–1355. [CrossRef]

6. Lim, M.A.; Pranata, R.; Huang, I.; Yonas, E.; Soeroto, A.Y.; Supriyadi, R. Multiorgan Failure with Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis. Can. J. Kidney Health Dis. 2020, 7, 205438120938573. [CrossRef]

7. Carriazo, S.; Kanbay, M.; Ortiz, A. Kidney disease and electrolytes in COVID-19: More than meets the eye. Clin. Kidney. J. 2020, 13, 274–280. [CrossRef] [PubMed]

8. Chen, Y.T.; Shao, S.C.; Lai, E.C.C.; Hung, M.J.; Chen, Y.C. Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: A systematic review and meta-analysis. Crit. Care 2020, 1–4. [CrossRef] [PubMed]

9. Cheruiyot, I.; Kipkorir, V.; Ngure, B.; Misiani, M.; Munguti, J.; Henry, B.; Lippi, G. Acute Kidney Injury is Associated with Worse Prognosis in COVID-19 Patients: A systematic review and Meta-analysis. Acta Biomed. 2020, 91, 1–19. [CrossRef]

10. Durvasula, R.; Wellington, T.; McNamara, E.; Watnick, S. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience from Seattle. Am. J. Kidney Dis. 2020, 76, 4–6. [CrossRef] [PubMed]

11. Ali, N.; Mahmood, S. Kidney Injury in COVID-19: An Emerging Concern to the Clinician. SN Compr. Clin. Med. 2020, 2, 1808–1809. [CrossRef]

12. Meena, P.; Bhargava, V.; Rana, D.S.; Bhalla, A.K.; Gupta, A. COVID-19 and the kidney: A matter of concern. Curr. Med. Res. Pract. 2020, 10, 165–168. [CrossRef] [PubMed]

13. Abd El-Aziz, T.M.; Stockand, J.D. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) an update on the status. Infect. Genet. Evol. 2020, 83, 104327. [CrossRef] [PubMed]

14. Lega, S.; Naviglio, S.; Volpi, S.; Tommasini, A. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. Vaccines 2020, 8, 224. [CrossRef] [PubMed]

15. Ahsan, W.; Alhazmi, H.A.; Patel, K.S.; Mangla, B.; Al Bratty, M.; Javed, S.; Najmi, A.; Sultan, M.H.; Makeen, H.A.; Khalid, A.; et al. Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. Front. Public. Health 2020, 8, 384. [CrossRef]

16. Patel, N.; Rein, J.L.; Sanchez-Russo, L.; Winston, J.; Uribarri, J. COVID-19-Associated Acute Kidney Injury: A Case Series. Kidney Med. 2020, 2, 668–669. [CrossRef]

17. Batiha, G.E.; Beshbishy, A.M.; Ikram, M.; Mulla, Z.S.; El-Hack, M.E.A.; Taha, A.E.; Algammal, A.M.; Elewa, Y.H.A. The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. Foods 2020, 9, 374. [CrossRef]

18. Darband, S.G.; Kaviani, M.; Yousefi, B.; Sadighparvar, S.; Pakdel, F.G.; Attari, J.A.; Mohebbi, I.; Naderi, S.; Majidinia, M. Quercetin: A functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer. J. Cell. Physiol. 2018, 233, 6544–6560. [CrossRef]

19. Diniz, L.R.L.; Filho, C.S.M.B.; Fielding, B.C.; de Sousa, D.P. Natural Antioxidants: A Review of Studies on Human and Animal Coronavirus. Oxidative Med. Cell. Longev. 2020, 2020, 1–14. [CrossRef]

20. Yao, F.; Zhang, R.; Fu, R.; He, W. Preventive and therapeutic effects of quercetin on hyperuricemia and renal injury in rats. J. Hyg. Res. 2011, 40, 175–177.
21. Shoskes, D.A. Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: A new class of renoprotective agents. *Transplantation* 1998, 66, 147–152. [CrossRef] [PubMed]

22. Wang, C.; Pan, Y.; Zhang, Q.Y.; Wang, F.M.; Kong, L.D. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. *PLoS ONE* 2012, 7, e38285. [CrossRef] [PubMed]

23. Tan, J.; He, J.; Qin, W.; Zhao, L. Quercetin alleviates lipopolysaccharide-induced acute kidney injury in mice by suppressing TLR4/NF-kappaB pathway. *Nan Fang Yi Ke Da Xue Xue Bao* 2019, 39, 598–602. [CrossRef] [PubMed]

24. Tan, R.Z.; Wang, C.; Deng, C.; Zhong, X.; Yan, Y.; Luo, Y.; Lan, H.Y.; He, T.; Wang, L. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-kappaB signaling maintained macrophage inflammation. *Phytother. Res.* 2020, 34, 139–152. [CrossRef]

25. Chaudhary, S.; Ganjoo, P.; Raisuddin, S.; Parvez, S. Nephroprotective activities of quercetin with potential relevance to oxidative stress induced by valproic acid. *Protoplasma* 2015, 252, 209–217. [CrossRef]

26. Gomes, I.B.; Porto, M.L.; Santos, M.C.L.; Campagnaro, B.P.; Pereira, T.M.; Meyrelles, S.S.; Vasquez, E.C. Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6 model of diabetic nephropathy. *Lipids Health Dis.* 2014, 13, 1–10. [CrossRef]

27. Morales, A.I.; Vicente-Sánchez, C.; Sandoval, J.M.S.; Egido, J.; Mayoral, P.; Árévalo, M.A.; Fernández-Tagarro, M.; López-Novoa, J.M.; Pérez-Barriocanal, F. Protective effect of quercetin on experimental chronic cadmium nephrotoxicity in rats is based on its antioxidant properties. *Food Chem. Toxicol.* 2006, 44, 2092–2100. [CrossRef]

28. Lu, H.; Wu, L.; Liu, L.; Ruan, Q.; Zhang, X.; Hong, W.; Wu, S.; Jin, G.; Bai, Y. Quercetin ameliorates kidney injury and fibrosis by modulating M1/M2 macrophage polarization. *Biochem. Pharmacol.* 2018, 154, 203–212. [CrossRef]

29. Elbe, H.; Dogan, Z.; Taslidere, E.; Cetin, A.; Turkoz, Y. Beneficial effects of quercetin on renal injury and oxidative stress caused by ciprofloxacin in rats: A histological and biochemical study. *Hum. Exp. Toxicol.* 2016, 35, 276–281. [CrossRef]

30. Koza, Y. Acute kidney injury: Current concepts and new insights. *J. Inj. Violence Res.* 2016, 8, 58–62. [CrossRef]

31. Hoste, E.A.; de Corte, W. AKI patients have worse long-term outcomes, especially in the immediate post-ICU period. *Crit. Care* 2012, 16, 1–2. [CrossRef] [PubMed]

32. Singbartl, K.; Kellum, J.A. AKI in the ICU: Definition, epidemiology, risk stratification, and outcomes. *Kidney Int.* 2012, 81, 819–825. [CrossRef] [PubMed]

33. Hoste, E.A.; Bagshaw, S.M.; Bellomo, R.; Cely, C.M.; Colman, R.; Cruz, D.N.; Edipidis, K.; Forni, L.G.; Gomersall, C.D.; Govil, D.; et al. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. *Intensive Care Med.* 2015, 41, 1411–1423. [CrossRef] [PubMed]

34. Doi, K.; Rabb, H. Impact of acute kidney injury on distant organ function: Recent findings and potential therapeutic targets. *Kidney Int.* 2016, 89, 555–564. [CrossRef]

35. Yu, S.M.W.; Bonventre, J.V. Acute Kidney Injury and Progression of Diabetic Kidney Disease. *Adv. Chronic Kidney Dis.* 2018, 25, 166–180. [CrossRef]

36. Truche, A.S.; Ragey, S.P.; Souweine, B.; Bailly, S.; Zafrani, L.; Bouadma, L.; Clech, C.; Garroustes-Orgeas, M.; Lacave, G.; Schwobel, C.; et al. ICU survival and need of renal replacement therapy with respect to AKI duration in critically ill patients. *Ann. Intensive Care* 2018, 8, 127. [CrossRef]

37. Abdelaziz, T.S.; Fouda, R.; Hussin, W.M.; Elyamny, M.S.; Abdelhamid, Y.M. Preventing acute kidney injury and improving outcome in critically ill patients utilizing risk prediction score (PRAIOC-RISKS) study. A prospective controlled trial of AKI prevention. *J. Nephrol.* 2020, 33, 325–334. [CrossRef]

38. Koeeze, J.; Keus, F.; Dieperink, W.; van der Horst, I.C.C.; Zijlstra, J.G.; van Meurs, M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. *BMC Nephrol.* 2017, 18, 70. [CrossRef]

39. Liu, K.D.; Yang, J.; Tan, T.C.; Glidden, D.V.; Zheng, S.; Pravoverov, L.; Hsu, C.; Go, A.S. Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort. *Am. J. Kidney Dis.* 2019, 73, 163–173. [CrossRef]

40. Dylewska, M.; Chomicka, I.; Malyszko, J. Hypertension in patients with acute kidney injury. *Wiad. Lek.* 2019, 72, 2199–2201. [CrossRef]
41. Peerapornratana, S.; Manrique-Caballero, C.L.; Gomez, H.; Kellum, J.A. Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment. *Kidney Int.* 2019, 96, 1083–1099. [CrossRef] [PubMed]

42. Pereira, M.; Rodrigues, N.; Godinho, I.; Gameiro, J.; Neves, M.; Gouveia, J.; Costa, E.S.Z.; Lopes, J.A. Acute kidney injury in patients with previous severe sepsis or septic shock: A comparison between the ‘Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease’ (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. *Clin. Kidney J.* 2017, 10, 332–340. [CrossRef]

43. Ülger, F.; Küçük, M.P.; Küçük, A.O.; Ikaya, N.K.; Murat, N.; Bilgiç, B.; Abanoz, H. Evaluation of acute kidney injury (AKI) with RIFLE, AKIN, CK, and KDIGO in critically ill trauma patients. *Eur. J. Trauma Emerg. Surg.* 2018, 44, 597–605. [CrossRef] [PubMed]

44. Teo, S.H.; Endre, Z.H. Biomarkers in acute kidney injury (AKI). *Best Pract. Res. Clin. Anaesthesiol.* 2017, 31, 331–344. [CrossRef] [PubMed]

45. Tsai, T.Y.; Chien, H.; Tsai, F.C.; Pan, H.C.; Yang, H.Y.; Lee, S.Y.; Hsu, H.H.; Fang, J.T.; Yang, C.W.; Chen, Y.C. Comparison of RIFLE, AKIN, and KDIGO classifications for assessing prognosis of patients on extracorporeal membrane oxygenation. *J. Formos. Med. Assoc.* 2017, 116, 844–851. [CrossRef]

46. Park, S.; Lee, H. Acute kidney injury prediction models: Current concepts and future strategies. *Curr. Opin. Nephrol. Hypertens.* 2019, 28, 552–559. [CrossRef]

47. Grooth, H.J.; Parienti, J.J.; Schetz, M. AKI biomarkers are poor discriminants for subsequent need for renal replacement therapy, but do not disqualify them yet. *Intensive Care Med.* 2018, 44, 1156–1158. [CrossRef]

48. Luft, F.C. Biomarkers and predicting acute kidney injury. *Acta Physiol. (Oxf.)* 2020, e13479. [CrossRef]

49. Zdziechowska, M.; Gluba-Brzózka, A.; Poliwczak, A.R.; Franczyk, B.; Kidawa, M.; Zielińska, M.; Rysz, J. Serum NGAL, KIM-1, IL-18, L-FABP: New biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. *Int. Urol. Nephrol.* 2020, 52, 2135–2143. [CrossRef]

50. Gayat, E. Biomarkers of acute kidney injury: Mixed results and huge heterogeneity of reporting. *BMJ Evid. Based Med.* 2019, 24, e9. [CrossRef]

51. Bunz, H.; Weyrich, P.; Peter, A.; Baumann, D.; Tschritter, O.; Peter, A.; Baumann, D.; Tschritter, O.; Gutho, W. Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway. *Cell. Physiol. Biochem.* 2017, 41, 769–783. [CrossRef] [PubMed]

52. Tian, L.; Shao, X.; Xie, Y.; Wang, Q.; Che, X.; Zhang, M.; Xu, W.; Xu, Y.; Ni, Z.; Mou, S. Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway. *Cell. Physiol. Biochem.* 2017, 41, 769–783. [CrossRef] [PubMed]

53. Han, S.J.; Lee, H.T. Mechanisms and therapeutic targets of ischemic acute kidney injury. *Kidney Res. Clin. Pract.* 2019, 38, 427–440. [CrossRef] [PubMed]

54. Agarwal, A.; Dong, Z.; Harris, R.; Murray, P.; Parikh, S.M.; Rosner, M.H.; Kellum, J.A.; Ronco, C. Cellular and Molecular Mechanisms of AKI. *J. Am. Soc. Nephrol.* 2016, 27, 1288–1299. [CrossRef] [PubMed]

55. Dong, Y.; Zhang, Q.; Wen, J.; Chen, T.; He, L.; Wang, Y.; Yin, J.; Wu, R.; Xue, R.; Li, S.; et al. Ischemic Duration and Frequency Determines AKI-to-CKD Progression Monitored by Dynamic Changes of Tubular Biomarkers in IRI Mice. *Front. Physiol.* 2019, 10, 153. [CrossRef]

56. Prasad, N.; Patel, M.R. Infection-Induced Kidney Diseases. *Front. Med. (Lausanne)* 2018, 5, 327:1–327:11. [CrossRef]

57. Prakash, J.; Gupta, T.; Prakash, S.; Rathore, S.S.; Sunder, S. Acute kidney injury in patients with human immunodeficiency virus infection. *Indian. J. Nephrol.* 2015, 25, 86–90. [CrossRef]

58. Moretti, M.; Lava, S.A.G.; Zgraggen, L.; Simonetti, G.D.; Kottanattu, L.; Bianchetti, M.G.; Milani, G.P. Acute kidney injury in symptomatic primary Epstein-Barr virus infectious mononucleosis: Systematic review. *J. Clin. Virol.* 2017, 91, 12–17. [CrossRef]

59. Moudgil, A.; Nast, C.C.; Bagga, A.; Wei, L.; Nurmamet, A.; Cohen, A.H.; Jordan, S.C.; Toyoda, M. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. *Kidney Int.* 2001, 59, 2126–2133. [CrossRef]

60. Fujinaga, S.; Hara, T. Acute Kidney Injury Following Plastic Bronchitis Associated with Influenza B Virus in a Child with Nephrotic Syndrome. *Indian Pediatr.* 2015, 52, 523–525. [CrossRef]
61. Brown, P.R.; Sadiq, O.; Weick, A.; Lenhart, A.; Elbatta, M.; Fernandez, C.; Kutait, A.; Pompa, R.; Jafari, S.M. Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir. *Hepatol. Commun.* 2018, 2, 1172–1178. [CrossRef] [PubMed]

62. Liu, T.; Tang, L.; Tang, H.; Pu, J.; Gong, S.; Fang, D.; Zhang, H.; Li, Y.P.; Zhu, X.; Wang, W.; et al. Zika Virus Infection Induces Acute Kidney Injury Through Activating NLRP3 Inflammasome Via Suppressing Bcl-2. *Front. Immunol.* 2019, 10, 1925. [CrossRef]

63. Khalil, M.A.; Sarwar, S.; Chaudry, M.A.; Maqbool, B.; Khalil, Z.; Tan, J.; Yaqub, S.; Hussain, S.A. Acute kidney injury in dengue virus infection. *Clin. Kidney J.* 2012, 5, 390–394. [CrossRef] [PubMed]

64. Casas-Aparicio, G.A.; Léon-Rodríguez, I.; Hernández-Zenteno, R.J.; Castillejos-López, M.; Alvarado-de Barrera, C.A.; Ormsby, C.E.; Reyes-Teran, G. Aggressive fluid accumulation is associated with acute kidney injury and mortality in a cohort of patients with severe pneumonia caused by influenza A H1N1 virus. *PLoS ONE* 2018, 13, e0192592. [CrossRef] [PubMed]

65. Han, D.; Liu, Z.; Han, Q.; Li, Z.; Zhang, G.; Qiu, J.; Lou, S.; Li, N.; Wang, Y.; Li, M. Acute kidney injury in patients with hemorrhagic fever with renal syndrome caused by Hantaan virus: Comparative evaluation by RIFLE and AKIN criteria. *Vector Borne Zoonotic Dis.* 2011, 11, 723–730. [CrossRef] [PubMed]

66. Libraty, D.H.; Makela, S.; Vlk, J.; Hurme, M.; Vaheri, A.; Ennis, F.A.; Mustonen, J. The degree of leukocytosis and urine GATA-3 mRNA levels are risk factors for severe acute kidney injury in Puumala virus nephropathia epidemica. *PLoS ONE* 2012, 7, e35402. [CrossRef] [PubMed]

67. Nadkarni, G.N.; Patel, A.; Simoes, P.K.; Yacoub, R.; Kamat, S.; Konstantinidis, I.; Perumalswami, P.; Branch, A.; Coca, S.G. Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: A nationwide inpatient sample analysis. *J. Viral Hepat.* 2016, 23, 32–38. [CrossRef] [PubMed]

68. Gupta, A.; Quigg, R.J. Glomerular Diseases Associated With Hepatitis B and C. *Adv. Chronic Kidney Dis.* 2015, 22, 343–351. [CrossRef] [PubMed]

69. Morisue, A.; Fukuoka, K.; Goto, R.; Ota, K.; Yamashita, H.; Shinno, Y.; Yamadori, I. Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon. *CEN Case Rep.* 2015, 4, 38–42. [CrossRef]

70. Nadasdy, T.; Hebert, L.A. Infection-related glomerulonephritis: Understanding mechanisms. *Semin. Nephrol.* 2011, 31, 369–375. [CrossRef]

71. Godinho, I.; Nogueira, E.; Jorge, S.; Alves, A.T.; da Costa, A.G. Membranoproliferative glomerulonephritis and interstitial nephritis in the setting of Epstein-Barr virus-related hemophagocytic syndrome. *Clin. Nephrol.* 2018, 89, 474–479. [CrossRef] [PubMed]

72. Abdulkader, R.C.; Ho, Y.L.; Santos, S.S.; Caires, R.; Arantes, M.F.; Andrade, L. Characteristics of acute kidney injury in patients infected with the 2009 influenza A (H1N1) virus. *Clin. J. Am. Soc. Nephrol.* 2010, 5, 1916–1921. [CrossRef]

73. Indhumathi, E.; Makkena, V.K.; Mamidi, V.; Jayaprakash, V.; Jayakumar, M. Influenza A (H1N1) Virus Infection Associated Acute Kidney Injury-A Study from a Tertiary Care Center in South India. *Saudi J. Kidney Dis. Transpl.* 2020, 31, 759–766. [CrossRef] [PubMed]

74. Salter, T.; Burton, H.; Douthwaite, S.; Newsholme, W.; Horsfield, C.; Hilton, R. Immune Complex Mediated Glomerulonephritis with Acute Thrombotic Microangiopathy following Newly Detected Hepatitis B Virus Infection in a Kidney Transplant Recipient. *Case Rep. Transplant.* 2016, 2016, 1–5. [CrossRef]

75. Kawakita, C.; Kinomura, M.; Otaka, N.; Kitagawa, M.; Sugiyama, H.; Kusano, N.; Mizuno, M.; Wada, J. HIV-associated Immune Complex Kidney Disease with C3-dominant Deposition Induced by HIV Infection after Treatment of IgA Nephropathy. *Intern. Med.* 2019, 58, 3001–3007. [CrossRef] [PubMed]

76. Tajima, K.; Kohno, K.; Shiono, Y.; Suzuki, I.; Kato, Y.; Hiroshima, Y.; Yamamoto, M.; Ohtake, H.; Ibawa, A.; Yamakawa, M.; et al. Acute kidney injury and inflammatory immune reconstitution syndrome in mixed genotype (A/E) hepatitis B virus co-infection in HIV-associated lymphoma. *Int. J. Clin. Exp. Pathol.* 2013, 6, 536–542. [PubMed]

77. Garg, S.; Hoenig, M.; Edwards, E.M.; Bliss, C.; Heeren, T.; Tumilty, S.; Walley, A.Y.; Koziel, M.J.; Skolnik, P.R.; Horsburgh, C.R.; et al. Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection. *AIDS Patient Care STDS* 2011, 25, 135–141. [CrossRef]
78. Cohen, S.D.; Chawla, L.S.; Kimmel, P.L. Acute kidney injury in patients with human immunodeficiency virus infection. *Curr. Opin. Crit. Care* 2008, 14, 647–653. [CrossRef] [PubMed]

79. Michal, J.L.; Rab, S.; Patel, M.; Kyle, A.W.; Miller, L.S.; Easley, K.A.; and Kalapila, A.G. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic. *AIDS Res. Hum. Retroviruses* 2018, 34, 690–698. [CrossRef] [PubMed]

80. Ou, X.; Mao, S.; Jiang, Y.; Zhang, S.; Ke, C.; Ma, G.; Cheng, A.; Wang, M.; Zhu, D.; Chen, S.; et al. Viral-host interaction in kidney reveals strategies to escape host immunity and persistently shed virus to the urine. *Oncotarget* 2017, 8, 7336–7349. [CrossRef]

81. Chaibi, K.; Dao, M.; Pham, T.; Gumucio-Sanguino, V.D.; Di Paolo, F.A.; Pavot, A.; Cohen, Y.; Dreyfuss, D.; Perez-Fernandez, X.; Gaudry, S. Severe Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome. *Am. J. Respir. Crit. Care Med.* 2020, 1–11. [CrossRef]

82. Gabarre, P.; Dumas, G.; Dupont, T.; Darmon, M.; Azoulay, E.; Zafrani, L. Acute kidney injury in critically ill patients with COVID-19. *Intensive Care Med.* 2015, 46, 1339–1348. [CrossRef] [PubMed]

83. Yang, F.; Shi, S.; Zhu, J.; Shi, J.; Dai, K.; Chen, X. Analysis of 92 deceased patients with COVID-19. *J. Med. Virol.* 2020, 92, 2511–2515. [CrossRef]

84. Yang, X.; Jin, Y.; Li, R.; Zhang, Z.; Sun, R.; Chen, D. Prevalence and impact of acute renal impairment on COVID-19: A systematic review and meta-analysis. *Crit. Care* 2020, 24, 1–8. [CrossRef]

85. Gagliardi, I.; Patella, G.; Michael, A.; Serra, R.; Provenzanno, M.; Andreucci, M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. *J. Clin. Med.* 2020, 9, 2506. [CrossRef] [PubMed]

86. Hirpara, K.V.; Aggarwal, P.; Mukherjee, A.J.; Joshi, N.; Burman, A.C. Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. *Anti-Cancer Agents Med. Chem.* 2009, 9, 138–161. [CrossRef]

87. Li, Y.; Yao, J.; Han, C.; Yang, J.; Chaudhry, M.T.; Wang, S.; Liu, H.; Yin, Y. Quercetin, Inflammation and Immunity. *Nutrients* 2016, 8, 167. [CrossRef] [PubMed]

88. Dunnick, J.K.; Hailey, J.R. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. *Fundam. Appl. Toxicol.* 1992, 19, 423–431. [CrossRef]

89. Li, G.; Zeng, X.; Xie, Y.; Cai, Z.; Moore, J.C.; Yuan, X.; Cheng, Z.; Ji, G. Pharmacokinetic properties of isorhamnetin, kaempferol and quercetin after oral gavage of total flavones of Hippophae rhamnoides L. in rats using a UPLC-MS method. *Fitoterapia* 2012, 83, 182–191. [CrossRef] [PubMed]

90. Hollman, P.C.H.; van Trijp, J.M.P.; Buysman, M.N.C.P.; vd Gaag, M.S.; Mengelers, M.J.B.; de Vries, J.H.M.; Katan, M.B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. *FEBS Lett.* 1997, 418, 152–156. [CrossRef]

91. Kahraman, A.; Erkasp, N.; Koken, T.; Serteser, M.; Aktepe, F.; Erkasp, S. The antioxidative and antiarthritic properties of quercetin in ethanol-induced gastric lesions. *Toxicology* 2003, 183, 133–142. [CrossRef]

92. Karuppagounder, V.; Arumugam, S.; Thandavarayan, R.A.; Sreedhar, R.; Giridharan, V.V.; Watanabe, K. Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis. *Drug Discov. Today* 2016, 21, 632–639. [CrossRef] [PubMed]

93. Dabulici, C.M.; Sarbu, I.; Vamanu, E. The Bioactive Potential of Functional Products and Bioavailability of Phenolic Compounds. *Foods* 2020, 9, 953. [CrossRef] [PubMed]

94. Zhang, M.; Swarts, S.G.; Yin, L.; Liu, C.; Tian, Y.; Cao, Y.; Swarts, M.; Yang, S.; Zhang, S.B.; Zhang, K.; et al. Antioxidant properties of quercetin. *Adv. Exp. Med. Biol.* 2011, 701, 283–289. [CrossRef] [PubMed]

95. Mamani-Matsuda, M.; Kauss, T.; Al-Kharrat, A.; Rambert, J.; Fawaz, F.; Thiolat, D.; Moynet, D.; Coves, S.; Malvy, D.; Mossalayi, M.D. Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. *Biochem. Pharmacol.* 2006, 72, 1304–1310. [CrossRef]

96. Das, M.; Ray, P.K. Lipid antioxidant properties of quercetin in vitro. *Biochem. Int.* 1988, 17, 203–209.

97. Park, H.R.; Yoon, H.; Kim, M.K.; Lee, S.D.; Chong, Y. Synthesis and antiviral evaluation of 7-O-arylmethylquercetin derivatives against SARS-associated coronavirus (SCV) and hepatitis C virus (HCV). *Arch. Pharm. Res.* 2012, 35, 77–85. [CrossRef]

98. Choi, H.J.; Kim, J.H.; Lee, C.H.; Ahn, Y.J.; Song, J.H.; Baek, S.H.; Kwon, D.H. Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus. *Antivir. Res.* 2009, 81, 77–81. [CrossRef]
99. Kim, H.P.; Mani, I.; Iversen, L.; Ziboh, V.A. Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipooxygenase from guinea-pigs. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58, 17–24. [CrossRef]

100. Bureau, G.; Longpre, F.; Martinoli, M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 2008, 86, 403–410. [CrossRef]

101. Lee, K.M.; Hwang, M.K.; Lee, D.E.; Lee, K.W.; Lee, H.J. Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J. Agric. Food Chem. 2010, 58, 5815–5820. [CrossRef] [PubMed]

102. Endale, M.; Park, S.C.; Kim, S.; Kim, S.H.; Yang, Y.; Cho, J.Y.; Rhee, M.H. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-kappaB-induced inflammatory mediators production in RAW 264.7 cells. Immunochemistry 2013, 218, 1452–1467. [CrossRef] [PubMed]

103. Kandere-Grzybowska, K.; Kempuraj, D.; Cao, J.; Cetrulo, C.L.; Theoharides, T.C. Regulation of IL-1-induced vasoconstriction through LKB1-AMPK signaling pathway. Curr. Med. Chem. 2018, 25, 146–153. [CrossRef]

104. Stewart, L.K.; Soileau, J.L.; Ribnicky, D.; Wang, Z.Q.; Raskin, I.; Poulev, A.; Majewski, M.; Cefalu, W.T.; Dumke, C.L.; Utter, A.C.; McAnulty, S.R.; et al. Quercetin reduces illness but not immune perturbations after intense exercise. Med. Sci. Sport. Exerc. 2007, 39, 1561–1569. [CrossRef]

105. Nieman, D.C.; Henson, D.A.; Gross, S.J.; Jenkins, D.P.; Davis, J.M.; Murphy, E.A.; Carmichael, M.D.; Park, S.C.; Kim, S.; Cho, J.Y.; Rhee, M.H. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-kappaB-induced inflammatory mediators production in RAW 264.7 cells. Immunochemistry 2013, 218, 1452–1467. [CrossRef] [PubMed]

106. Kandere-Grzybowska, K.; Kempuraj, D.; Cao, J.; Cetrulo, C.L.; Theoharides, T.C. Regulation of IL-1-induced vasoconstriction through LKB1-AMPK signaling pathway. Curr. Med. Chem. 2018, 25, 146–153. [CrossRef] [PubMed]

107. Kim, S.G.; Kim, J.R.; Choi, H.C. Quercetin-Induced AMP-Activated Protein Kinase Activation Attenuates Vasoconstriction Through LKB1-AMPK Signaling Pathway. J. Med. Food 2018, 21, 146–153. [CrossRef] [PubMed]

108. Marunaka, Y. Actions of quercetin, a flavonoid, on ion transporters: Its physiological roles. Ann. N. Y. Acad. Sci. 2017, 1398, 142–151. [CrossRef] [PubMed]

109. Marunaka, Y.; Niisato, N.; Miyazaki, H.; Nakajima, K.I.; Taruno, A.; Sun, H.; Marunaka, R.; Okui, M.; Yamamoto, T.; Kanamura, N. Quercetin is a Useful Medicinal Compound Showing Various Actions Including Control of Blood Pressure, Neurite Elongation and Epithelial Ion Transport. Curr. Med. Chem. 2018, 25, 4876–4887. [CrossRef] [PubMed]

110. Kahraman, A.; Erkasp, N.; Serteser, M.; Koken, T. Protective effect of quercetin on renal ischemia/reperfusion injury in rats. J. Nephrol. 2003, 16, 219–224. [PubMed]

111. Inal, M.; Altimisik, M.; Bilgin, M.D. The effect of quercetin on renal ischemia and reperfusion injury in the rat. Cell Biochem. Funct. 2002, 20, 291–296. [CrossRef] [PubMed]

112. Sanéchez-González, P.D.; López-Hernández, F.J.; Dueñas, M.; Prieto, M.; Sánchez-López, E.; Thomale, J.; Ruiz-Ortega, M.; López-Novoa, J.M.; Morales, A.I. Differential effect of quercetin on cisplatin-induced toxicity in kidney and tumor tissues. Food Chem. Toxicol. 2017, 107, 226–236. [CrossRef]
118. Yuksel, Y.; Yuksel, R.; Yagmurca, M.; Haltsa, H.; Erdamar, H.; Toktas, M.; Ozcan, O. Effects of quercetin on methotrexate-induced nephrotoxicity in rats. Hum. Exp. Toxicol. 2017, 36, 51–61. [CrossRef]

119. Erboga, M.; Aktas, C.; Erboga, Z.F.; Donmez, Y.B.; Gurel, A. Quercetin ameliorates methotrexate-induced renal damage, apoptosis and oxidative stress in rats. Ren. Fail. 2015, 37, 1492–1497. [CrossRef]

120. Vicente-Vicente, L.; González-Calle, D.; Casanova, A.G.; Hernández-Sánchez, M.T.; Prieto, M.; Rama-Merchán, J.C.; Martín-Moreiras, J.; Martín-Herrero, F.; Sánchez, P.L.; López-Hernández, F.J.; et al. Quercetin, a Promising Clinical Candidate for The Prevention of Contrast-Induced Nephropathy. Int. J. Mol. Sci. 2019, 20, 4961. [CrossRef]

121. Nabavi, S.M.; Nabavi, S.F.; Habtemariam, S.; Moghaddam, A.H.; Latifi, A.M. Ameliorative effects of quercetin on sodium fluoride-induced oxidative stress in rat’s kidney. Ren. Fail. 2012, 34, 901–906. [CrossRef]

122. Shin, Y.J.; Kim, I.J.; Kim, Y.J.; Kim, W.H.; Park, E.Y.; Kim, I.Y.; Shin, H.S.; Kim, K.S.; Lee, E.K.; Chung, K.H.; et al. Protective Effects of Quercetin Against HgCl2-Induced Nephrotoxicity in Sprague-Dawley Rats. J. Med. Food 2015, 18, 524–534. [CrossRef] [PubMed]

123. Bahar, E.; Lee, G.H.; Bhattarai, K.R.; Lee, H.Y.; Kim, H.K.; Handigund, M.; Choi, M.K.; Han, S.Y.; Chae, H.J.; Yoon, H. Protective role of quercetin against manganese-induced injury in the liver, kidney, and lung; and hematological parameters in acute and subchronic rat models. Drug Des. Dev. Ther. 2017, 11, 2605–2619. [CrossRef] [PubMed]

124. Renugadevi, J.; Prabu, S.M. Quercetin protects against oxidative stress-related renal dysfunction by cadmium in rats. Exp. Toxicol. Pathol. 2010, 62, 471–481. [CrossRef] [PubMed]

125. Gholampour, F.; Sadidi, Z. Hepatorenal protection during renal ischemia by quercetin and remote ischemic preconditioning. J. Surg. Res. 2018, 231, 224–233. [CrossRef] [PubMed]

126. Singh, D.; Chander, V.; Chopra, K. Quercetin, a bioflavonoid, attenuates ferric nitrilotriacetate-induced renal damage, apoptosis and oxidative stress in rats. Ren. Fail. 2015, 37, 1492–1497. [CrossRef]

127. Almaghrabi, O.A. Molecular and biochemical investigations on the effect of quercetin on oxidative stress induced by cisplatin in rat kidney. Saudi J. Biol. Sci. 2015, 22, 227–231. [CrossRef] [PubMed]

128. Kinaci, M.K.; Erkasap, N.; Kucuk, A.; Koken, T.; Tosun, M. Effects of quercetin on apoptosis, NF-kappaB and NOS gene expression in renal ischemia/reperfusion injury. Exp. Ther. Med. 2012, 3, 249–254. [CrossRef]

129. Liu, J.; Li, X.; Yue, Y.; Li, J.; He, T.; He, Y. The inhibitory effect of quercetin on IL-6 production by LPS-stimulated neutrophils. Cell. Mol. Immunol. 2005, 2, 455–460. [CrossRef]

130. Shu, B.; Feng, Y.; Gui, Y.; Lu, Q.; Wei, W.; Xue, X.; Sun, X.; He, W.; Yang, J.; Dai, C. Blockade of CD38 diminishes lipopolysaccharide-induced macrophage classical activation and acute kidney injury involving NF-kappaB signaling suppression. Cell. Signal. 2018, 42, 249–258. [CrossRef]

131. Chen, B.L.; Wang, L.T.; Huang, K.H.; Wang, C.C.; Chiang, C.K.; Liu, S.H. Quercetin attenuates renal ischemia/reperfusion injury via an activation of AMP-activated protein kinase-regulated autophagy pathway. J. Nutr. Biochem. 2014, 25, 1226–1234. [CrossRef] [PubMed]

132. Pei, B.; Yang, M.; Qi, X.; Shen, X.; Chen, X.; Zhang, F. Quercetin ameliorates ischemia/reperfusion-induced cognitive deficits by inhibiting ASK1/JNK3/caspase-3 by enhancing the Akt signaling pathway. Biochem. Biophys. Res. Commun. 2016, 478, 199–205. [CrossRef] [PubMed]

133. Nakamura, M.; Omura, S. Quercetin regulates the inhibitory effect of mononclonal non-specific suppressor factor beta on tumor necrosis factor-alpha production in LPS-stimulated macrophages. Biosci. Biotechnol. Biochem. 2008, 72, 1915–1920. [CrossRef] [PubMed]

134. Zhang, K.; Lin, S.; Wang, M.; Huang, J.; Zhu, Y. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. BioMed Res. Int. 2020, 2020, 1–8. [CrossRef]

135. Singh, D.; Chander, V.; Chopra, K. The effect of quercetin, a bioflavonoid on ischemia/reperfusion induced renal injury in rats. Arch. Med. Res. 2004, 35, 484–494. [CrossRef] [PubMed]

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.